Phesgo 40 mg (Trastuzumab SOLUTION) 40 MG

PHESGO 40 MG is a subcutaneous solution containing trastuzumab, used for targeted therapy in certain cancer treatments. This medication is designed to deliver precise doses for effective management.

Strength

40 MG

Manufacturer / TM Owner

HOFFMANN-LA ROCHE LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

PHESGO 40 MG is primarily used in the treatment of specific types of cancer, particularly those involving HER2-positive cells. It is often administered as part of a broader treatment plan to target and inhibit the growth of cancer cells. Patients may wonder, 'What is PHESGO 40 MG used for?' and the answer lies in its role in targeted cancer therapy.

Side Effects

Common effects of PHESGO 40 MG may include reactions at the injection site, such as redness, swelling, or pain. Some individuals might experience fatigue, nausea, or general discomfort. These effects vary among patients and are typically monitored by healthcare providers.

Precautions & Warnings

PHESGO 40 MG should be handled with care, following the guidelines provided by healthcare professionals. It is important to store the solution properly and administer it as directed. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

PHESGO 40 MG may interact with other medications, including those that affect the immune system or other cancer treatments. It is crucial to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of the treatment.

Frequently Asked Questions

PHESGO 40 MG is used in the treatment of certain types of cancer, particularly those involving HER2-positive cells.

PHESGO 40 MG is administered subcutaneously, typically by a healthcare professional.

Common side effects may include reactions at the injection site, fatigue, and nausea.

Potential interactions with other medications should be discussed with a healthcare provider.

PHESGO 40 MG should be stored according to the guidelines provided by the manufacturer.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.